170 related articles for article (PubMed ID: 19784481)
1. Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients.
Zenha EM; Ferreira MA; Foss NT
Braz J Med Biol Res; 2009 Oct; 42(10):968-72. PubMed ID: 19784481
[TBL] [Abstract][Full Text] [Related]
2. Anti-PGL-1 antibody levels in Thai leprosy patients.
Kampirapap K; Singtham N
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):728-33. PubMed ID: 9253875
[TBL] [Abstract][Full Text] [Related]
3.
Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
Front Immunol; 2018; 9():915. PubMed ID: 29867930
[TBL] [Abstract][Full Text] [Related]
4. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions.
Silva EA; Iyer A; Ura S; Lauris JR; Naafs B; Das PK; Vilani-Moreno F
Trop Med Int Health; 2007 Dec; 12(12):1450-8. PubMed ID: 18076551
[TBL] [Abstract][Full Text] [Related]
5. Alterations to antigen-specific immune responses before and after multidrug therapy of leprosy.
Freitas AA; Oliveira RM; Hungria EM; Cardoso LP; Sousa AL; Costa MB; Reed SG; Duthie MS; Stefani MM
Diagn Microbiol Infect Dis; 2015 Oct; 83(2):154-61. PubMed ID: 26233487
[TBL] [Abstract][Full Text] [Related]
6. Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.
Mizoguti Dde F; Hungria EM; Freitas AA; Oliveira RM; Cardoso LP; Costa MB; Sousa AL; Duthie MS; Stefani MM
Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):914-20. PubMed ID: 26560982
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium leprae particle agglutination in diagnosis and monitoring of treatment of leprosy.
Kampirapap K
J Med Assoc Thai; 1999 Oct; 82(10):1020-4. PubMed ID: 10561966
[TBL] [Abstract][Full Text] [Related]
9. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
[TBL] [Abstract][Full Text] [Related]
10. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
11. Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy.
Cho SN; Cellona RV; Villahermosa LG; Fajardo TT; Balagon MV; Abalos RM; Tan EV; Walsh GP; Kim JD; Brennan PJ
Clin Diagn Lab Immunol; 2001 Jan; 8(1):138-42. PubMed ID: 11139208
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769
[TBL] [Abstract][Full Text] [Related]
13. Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil.
Hungria EM; Oliveira RM; Souza AL; Costa MB; Souza VN; Silva EA; Moreno FR; Nogueira ME; Costa MR; Silva SM; Bührer-Sékula S; Reed SG; Duthie MS; Stefani MM
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():104-11. PubMed ID: 23283461
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients.
Miller RA; Gorder D; Harnisch JP
Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):633-6. PubMed ID: 3323367
[TBL] [Abstract][Full Text] [Related]
15. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction.
Stefani MM; Martelli CM; Morais-Neto OL; Martelli P; Costa MB; de Andrade AL
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):356-64. PubMed ID: 9934362
[TBL] [Abstract][Full Text] [Related]
16. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Hungria EM; Oliveira RM; Penna GO; Aderaldo LC; Pontes MA; Cruz R; Gonçalves HS; Penna ML; Kerr LR; Stefani MM; Bührer-Sékula S
Infect Dis Poverty; 2016 Dec; 5(1):110. PubMed ID: 27919284
[TBL] [Abstract][Full Text] [Related]
17. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.
Brito Mde F; Ximenes RA; Gallo ME; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():67-72. PubMed ID: 19618079
[TBL] [Abstract][Full Text] [Related]
18. PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy.
Chanteau S; Cartel JL; Celerier P; Plichart R; Desforges S; Roux J
Int J Lepr Other Mycobact Dis; 1989 Dec; 57(4):735-43. PubMed ID: 2681456
[TBL] [Abstract][Full Text] [Related]
19. Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients.
Drowart A; Chanteau S; Huygen K; De Cock M; Cartel JL; De Bruyn J; Launois P; Yernault JC; Van Vooren JP
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):29-34. PubMed ID: 8326178
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitor.
Prakash K; Sehgal VN; Aggarwal R
J Dermatol; 1993 Jan; 20(1):16-20. PubMed ID: 8482747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
